Evidence map›Paper›PMID 28603270›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2017

Impact of Integrated Care Model (ICM) on Direct Medical Costs in Management of Advanced Chronic Obstructive Pulmonary Disease (COPD).

Ewa Bandurska, Iwona Damps-Konstańska, Piotr Popowski, Tadeusz Jędrzejczyk, Piotr Janowiak, Katarzyna Świętnicka, Marzena Zarzeczna-Baran, Ewa Jassem

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Assessment of Renal and Hepatic Tissue-Protective Effects of N-Acetylcysteine via Ammonia Metabolism: A Prospective Randomized Study.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Cost-Effectiveness Analysis of Integrated Care in Management of Advanced Chronic Obstructive Pulmonary Disease (COPD).Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ewa BandurskaDepartment of Public Health and Social Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Iwona Damps-KonstańskaDepartment of Allergology, Medical University of Gdańsk, Gdańsk, Poland.
Piotr PopowskiDepartment of Public Health and Social Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Tadeusz JędrzejczykPublic Health and Social Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Piotr JanowiakDepartment of Allergology, Medical University of Gdańsk, Gdańsk, Poland.
Katarzyna ŚwiętnickaCoordination Center, University Clinical Center in Gdańsk, Gdańsk, Poland.
Marzena Zarzeczna-BaranDepartment of Public Health and Social Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Ewa JassemDepartment of Allergology, Medical University of Gdańsk, Gdańsk, Poland.
Gdańsk Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Chronic obstructive pulmonary disease (COPD) is a commonly diagnosed condition in people older than 50 years of age. In advanced stage of this disease, integrated care (IC) is recommended as an optimal approach. IC allows for holistic and patient-focused care carried out at the patient's home. The aim of this study was to analyze the impact of IC on costs of care and on demand for medical services among patients included in IC. MATERIAL AND METHODS The study included 154 patients diagnosed with advanced COPD. Costs of care (general, COPD, and exacerbations-related) were evaluated for 1 year, including 6-months before and after implementing IC. The analysis included assessment of the number of medical procedures of various types before and after entering IC and changes in medical services providers. RESULTS Direct medical costs of standard care in advanced COPD were 886.78 EUR per 6 months. Costs of care of all types decreased after introducing IC. Changes in COPD and exacerbation-related costs were statistically significant (p=0.012492 and p=0.017023, respectively). Patients less frequently used medical services for respiratory system and cardiovascular diseases. Similarly, the number of hospitalizations and visits to emergency medicine departments decreased (by 40.24% and 8.5%, respectively). The number of GP visits increased after introducing IC (by 7.14%). CONCLUSIONS The high costs of care in advanced COPD indicate the need for new forms of effective care. IC caused a decrease in costs and in the number of hospitalization, with a simultaneous increase in the number of GP visits.

Indexed as

Delivery of Health Care, IntegratedHealth Care CostsModels, TheoreticalAgedAged, 80 and overDisease ProgressionHumansMiddle AgedPulmonary Disease, Chronic Obstructive

Identifiers

PMID28603270
PMCPMC5478556
OpenAlexW2627052336

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.